安全信息
GHS Symbol
Precautionary statements | |
- P308+P313
- P201 Obtain special instructions before use. 使用前获取专门指示。
|
Hazard statements | |
- H360 May damage fertility or the unborn child 可能对生育能力或未出生婴儿造成伤害
- H303 May be harmfully swallowed 吞食可能有害
|
WGK Germany | 3 |
Signal word |
|
RTECS | TU3920000 |
Personal Protective Equipment |
Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges |
Hazard Codes |
T |
Safety Statements | |
- S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时,立即求医(可能时出示标签);
- S53 Avoid exposure - obtain special instructions before use 避免接触,使用前获得特别指示说明;
|
Risk Statements | |
- R61 May cause harm to the unborn child 可能对未出生的婴儿导致伤害
- R22 Harmful if swallowed 吞咽有害
|
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 13100 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540,
08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 6,44,1981
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka
Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959-
Volume(issue)/page/year: 21,2117,1979
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Human - man
DOSE/DURATION : 571 ug/kg
TOXIC EFFECTS :
Vascular - shock
Skin and Appendages - dermatitis, other (after systemic exposure)
Immunological Including Allergic - anaphylaxis
REFERENCE :
APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696,
Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 28,1310,1994
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 105 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo,
Japan) Volume(issue)/page/year: 6,516,1982
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Subcutaneous
SP
TYPE OF TEST : Unscheduled DNA synthesis
TEST SYSTEM : Human Cells - not otherwise specified
DOSE/DURATION : 1 nmol/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut
Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year:
43,2664,1983
TYPE OF TEST : DNA inhibition
TEST SYSTEM : Human Cells - not otherwise specified
DOSE/DURATION : 10 nmol/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut
Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year:
43,2664,1983
TYPE OF TEST : DNA inhibition
TEST SYSTEM : Rodent - mouse Cells - not otherwise specified
DOSE/DURATION : 1 nmol/L
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag,
Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
Volume(issue)/page/year: 36,1782,1986
TYPE OF TEST : DNA inhibition
TEST SYSTEM : Rodent - mouse Leukocyte
DOSE/DURATION : 10 nmol/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut
Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year:
43,2536,1983
TYPE OF TEST : Mutation test systems - not otherwise specified
ROUTE OF EXPOSURE : Administration onto the skin
TEST SYSTEM : Human
DOSE/DURATION : 5000 ppm
REFERENCE :
ARDEAC Archives of Dermatology. (AMA, 535 N. Dearborn St., Chicago, IL
60610) V.82- 1960- Volume(issue)/page/year: 103,39,1971
TYPE OF TEST : Mutation test systems - not otherwise specified
ROUTE OF EXPOSURE : Administration onto the skin
TEST SYSTEM : Human
DOSE/DURATION : 5000 ppm
REFERENCE :
26UYA8 "Psoriasis, Procee
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 1 mg/kg
SEX/DURATION : female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial
(including nose and tongue)
REFERENCE :
CGANE7 Congenital Anomalies. (Nippon Senten Ijo Gakkai, 377-2 Ono-higashi,
Osakasayama, Osaka-Fu 589 Japan) V.27- 1987- Volume(issue)/page/year:
35,133,1995
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 450 ug/kg
SEX/DURATION : fem
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Administration onto the skin
SPECIES OBSERVED : Human - woman
DOSE : 101 mg/kg
SEX/DURATION : female 12-29 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
e.g., stunted fetus)
Reproductive - Specific Developmental Abnormalities - gastrointestinal
system
REFERENCE :
AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co.,
11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920-
Volume(issue)/page/year: 162,396,1990
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 900 mg/kg
SEX/DURATION : female 11-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan
R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968-
Volume(issue)/page/year: 44,507,1991